LUPIN vs PGHL: Stock Comparison

Lupin Limited vs Procter & Gamble Health Limited

Live data: 22 July 2026, 3:04 PM IST • Source: NSE and company filings

Lupin Limited is the larger company by market capitalisation. Lupin Limited shows a lower P/E and faster revenue growth, while Procter & Gamble Health Limited shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Lupin Limited and Procter & Gamble Health Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, LUPIN is more favourable on 6 of 13 scored metrics and PGHL on 7These counts are context-free and are not an overall rating.

Key Differences

Market Cap
LUPIN is the larger company
₹1.1 L Cr vs ₹11,172 Cr
P/E Ratio
LUPIN has a lower P/E
21.56x vs 34.28x
P/B Ratio
LUPIN has a lower P/B
5.12x vs 21.36x
EPS
PGHL has higher earnings per share
₹196.64 vs ₹116.56
Dividend Yield
PGHL has a higher dividend yield
2.34% vs 0.48%
Revenue Growth (TTM YoY)
LUPIN has faster revenue growth
31.9% vs 19.1%
EPS Growth (TTM YoY)
LUPIN has faster EPS growth
89% vs 54.6%
Qtr Sales Growth
LUPIN has stronger quarterly sales growth
31.9% vs 19.1%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricLUPINPGHL
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricLUPINPGHL
Live Price₹2,408.8₹6,742
Day Change-4.22%-0.55%
Volume10.51 L4,674
52-Week High₹2,529.5₹6,975
52-Week Low₹1,836.8₹4,707
Distance from 52W High-4.77%-3.34%

Valuation

MetricLUPINPGHL
Market Cap₹1.1 L Cr₹11,172 Cr
P/E Ratio21.56x34.28x
P/B Ratio5.12x21.36x
EPS₹116.56₹196.64
Book Value₹491.29₹316.01
Dividend Yield0.48%2.34%

Growth

MetricLUPINPGHL
Revenue Growth (TTM YoY)31.9%19.1%
EPS Growth (TTM YoY)89%54.6%
Qtr Sales Growth31.9%19.1%
Qtr Profit Growth101%54.6%

Profitability & Leverage

MetricLUPINPGHL
ROE29.1%61.6%
ROCE30.3%83.5%
Net Margin17.65%23.22%
Operating Margin31.5%32.4%
Debt to Equity0.29x0.02x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricLUPINPGHL
Promoter Holding46.57% 0.04 pp0%
FII Holding21.71% 0.22 pp6.33% 0.13 pp
DII Holding25.32% 0.26 pp12.44% 1.23 pp
Public Holding6.11% 0.08 pp29.42% 1.11 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Lupin Limited and Procter & Gamble Health Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.